SAFETY DATA SHEET



SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1. Product identifier

Trade name or designation

of the mixture

PURINETHOL TABLETS

Registration number

PURI-NETHOL TABLETS * PURINETHOL TABLETS 25 MG * PURI-NETHOL TABLETS 50 MG * **Synonyms**

MERCAPTOPURINA WELLCOME COMPRIMIDOS * MERCAPTOPURINE MONOHYDRATE,

FORMULATED PRODUCT

Issue date 20-October-2014

Version number

20-October-2014 **Revision date**

1.2. Relevant identified uses of the substance or mixture and uses advised against

Identified uses Medicinal Product

> This safety data sheet is written to provide health, safety and environmental information for people handling this formulated product in the workplace. It is not intended to provide information relevant

to medicinal use of the product. In this instance patients should consult prescribing

information/package insert/product label or consult their pharmacist or physician. For health and safety information for individual ingredients used during manufacturing, refer to the appropriate

safety data sheet for each ingredient.

Uses advised against No other uses are advised.

1.3. Details of the supplier of the safety data sheet

GlaxoSmithKline UK 980 Great West Road

Brentford, Middlesex TW8 9GS UK

UK General Information (normal business hours): +44-20-8047-5000

Email Address: msds@gsk.com Website: www.gsk.com

1.4. Emergency telephone

number

TRANSPORT EMERGENCIES::

UK In-country toll call: +(44)-870-8200418 International toll call: +1 703 527 3887

available 24 hrs/7 days; multi-language response

SECTION 2: Hazards identification

2.1. Classification of the substance or mixture

Classification according to Directive 67/548/EEC or 1999/45/EC as amended

Exempt from requirements - product regulated as a medicinal product, cosmetic product or medical device.

Classification according to Regulation (EC) No 1272/2008 as amended

Exempt from requirements - product regulated as a medicinal product, cosmetic product or medical device.

2.2. Label elements

Label according to Regulation (EC) No. 1272/2008 as amended

Exempt from requirements - product regulated as a medicinal product, cosmetic product or medical device.

Assume that this product is capable of sustaining combustion. 2.3. Other hazards

Caution - Pharmaceutical agent. See section 11 for additional information on health hazards.

SECTION 3: Composition/information on ingredients

3.2. Mixtures

Material name: PURINETHOL TABLETS SDS MALTA **General information**

Chemical name % CAS-No. / EC No. REACH Registration No. INDEX No. Notes

MERCAPTOPURINE MONOHYDRATE 16 - < 40,3 6°

6112-76-1

Classification: DSD: Carc. Cat. 3;R40, Muta. Cat. 3;R68, Repr. Cat. 2;R60-61, Xn;R22-48/22,

R64. R52-53

CLP: Acute Tox. 4;H302, Muta. 2;H341, Carc. 2;H351, Repr. 1B;H360FD,

Lact.;H362, STOT RE 2;H373, Aquatic Chronic 3;H412

Starch 10 - < 20 9005-25-8 -

232-679-6

Classification: DSD: -

CLP: -

MAGNESIUM STEARATE < 1 557-04-0 -

209-150-3

Classification: DSD: -

CLP: -

Other components below reportable levels 50 - < 60

List of abbreviations and symbols that may be used above

CLP: Regulation No. 1272/2008.

DSD: Directive 67/548/EEC.

M: M-factor

vPvB: very persistent and very bioaccumulative substance.

PBT: persistent, bioaccumulative and toxic substance.

#: This substance has been assigned Community workplace exposure limit(s).

Composition comments The full text for all R- and H-phrases is displayed in section 16.

SECTION 4: First aid measures

General information

In the case of accident or if you feel unwell, seek medical advice immediately (show the label where possible). Ensure that medical personnel are aware of the material(s) involved, and take precautions to protect themselves.

The need for pre-placement and periodic health surveillance must be determined by risk assessment. Following assessment, if the risk of exposure is considered significant then exposed individuals should undergo appropriate health surveillance that may include symptom enquiry, clinical examination and monitoring of lead organ effects (e.g. full blood counts).

In the event of overexposure, individuals should receive post exposure health surveillance

focused on the most likely health effects (e.g. full blood counts).

4.1. Description of first aid measures

Inhalation If breathing is difficult, trained personnel should give oxygen. If not breathing, give artificial

respiration. Get medical attention immediately.

Skin contact Immediately flush with plenty of water for at least 15 minutes while removing contaminated clothing

and shoes. Remove and isolate contaminated clothing and shoes. Get medical attention

immediately.

Eye contact Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.

Ingestion If swallowed, rinse mouth with water (only if the person is conscious). Call a physician or poison

control centre immediately. Only induce vomiting at the instruction of medical personnel. Never

give anything by mouth to an unconsious person.

4.2. Most important symptoms and effects, both acute and delayed

Irritant effects. Prolonged exposure may cause chronic effects.

The following adverse effects have been noted with therapeutic use of this material: bone marrow

toxicity; nausea; vomiting; diarrhoea; anorexia; rash; hair loss.

4.3. Indication of any immediate medical attention and special treatment needed

No specific antidotes are recommended. Treat according to locally accepted protocols. For additional guidance, refer to the current prescribing information or to the local poison control information centre.

SECTION 5: Firefighting measures

General fire hazards Assume that this product is capable of sustaining combustion.

5.1. Extinguishing media

Suitable extinguishing media

Foam. Dry chemical powder. Carbon dioxide (CO2). Water.

Material name: PURINETHOL TABLETS

110573 Version #: 17 Revision date: 20-October-2014 Issue date: 20-October-2014

Unsuitable extinguishing

media

None known.

5.2. Special hazards arising from the substance or mixture

During fire, gases hazardous to health may be formed.

5.3. Advice for firefighters

Special protective equipment for firefighters

Self-contained breathing apparatus and full protective clothing must be worn in case of fire.

Special fire fighting procedures

Use water spray to cool unopened containers.

Specific methodsUse standard firefighting procedures and consider the hazards of other involved materials.

SECTION 6: Accidental release measures

6.1. Personal precautions, protective equipment and emergency procedures

For non-emergency personnel

Keep unnecessary personnel away. Keep people away from and upwind of spill/leak. Wear appropriate personal protective equipment. Ensure adequate ventilation. Local authorities should be advised if significant spillages cannot be contained. For personal protection, see section 8.

For emergency responders

Keep unnecessary personnel away. Use personal protection recommended in Section 8 of the

SDS.

6.2. Environmental precautions

Avoid release to the environment. Contact local authorities in case of spillage to drain/aquatic environment. Prevent further leakage or spillage if safe to do so. Do not contaminate water. Avoid discharge into drains, water courses or onto the ground.

6.3. Methods and material for containment and cleaning up

Stop the flow of material, if this is without risk. Collect spillage. Prevent product from entering

drains. Following product recovery, flush area with water.

6.4. Reference to other

sections

For personal protection, see section 8. For waste disposal, see section 13 of the SDS.

SECTION 7: Handling and storage

7.1. Precautions for safe handling

Obtain special instructions before use. Do not handle until all safety precautions have been read and understood. Do not taste or swallow. Avoid contact during pregnancy/while nursing. Avoid prolonged exposure. Provide adequate ventilation. Wear appropriate personal protective equipment. Observe good industrial hygiene practices. When using, do not eat, drink or smoke. Wash hands thoroughly after handling. Avoid release to the environment. Do not empty into

7.2. Conditions for safe storage, including any incompatibilities

Store locked up. Store in original tightly closed container. Store away from incompatible materials (see Section 10 of the SDS).

7.3. Specific end use(s) Medicinal Product

SECTION 8: Exposure controls/personal protection

8.1. Control parameters

Occupational exposure limits

GSK

Components	Туре	Value	Note
MAGNESIUM STEARATE (CAS 557-04-0)	OHC	1	
MERCAPTOPURINE MONOHYDRATE (CAS 6112-76-1)	8 HR TWA	10 mcg/m3	REPRODUCTIVE HAZARD, CARCINOGEN
·	OHC	4	REPRODUCTIVE HAZARD, CARCINOGEN

Biological limit values

No biological exposure limits noted for the ingredient(s).

Recommended monitoring

procedures

Follow standard monitoring procedures.

Derived no-effect level (DNEL)

Not available.

Predicted no effect concentrations (PNECs)

8.2. Exposure controls

Appropriate engineering

controls

An Exposure Control Approach (ECA) is established for operations involving this material based upon the OEL/Occupational Hazard Category and the outcome of a site- or operation-specific risk assessment. Use process enclosures, local exhaust ventilation, or other engineering controls to control airborne levels below recommended exposure limits.

Material name: PURINETHOL TABLETS

SDS MALTA

Individual protection measures, such as personal protective equipment

General information Personal protection equipment should be chosen according to the CEN standards and in

discussion with the supplier of the personal protective equipment. Follow all local regulations if

personal protective equipment (PPE) is used in the workplace.

Eye/face protection Eye wash fountain is recommended. Wear safety glasses with side shields (or goggles). (eg. EN

166)

Skin protection

- Hand protection The choice of an appropriate glove does not only depend on its material but also on other quality

features and is different from one producer to the other. Glove selection must take into account any solvents and other hazards present. Select suitable chemical resistant protective gloves (EN

374) with a protective index 6 (>480min permeation time).

- Other Wear appropriate chemical resistant clothing.

Respiratory protection When workers are facing concentrations above the exposure limit they must use appropriate

certified respirators.

Thermal hazards Wear appropriate thermal protective clothing, when necessary.

Hygiene measures An occupational/industrial hygiene monitoring method has been developed for this material. For

advice on suitable monitoring methods, seek guidance from a qualified environment, health and

safety professional.

Always observe good personal hygiene measures, such as washing after handling the material and before eating, drinking, and/or smoking. Routinely wash work clothing and protective equipment to remove contaminants. Do not get this material on clothing. Wash contaminated clothing before reuse. When using, do not eat, drink or smoke. New or expectant mothers might be at greater risk from overexposure. Risk assessments must take this into consideration. Female employees anticipating pregnancy or with a confirmed pregnancy must be encouraged to notify an occupational health professional or their line manager. This will act as the trigger for individual

re-assessment of the employee's work practices.

Environmental exposure controls

Hazard guidance and control recommendations

Contain spills and prevent releases and observe national regulations on emissions. Environmental manager must be informed of all major releases.

SECTION 9: Physical and chemical properties

9.1. Information on basic physical and chemical properties

Appearance

Physical state Solid.
Form Tablet.

Colour Not available.

Odour Not available.

Odour threshold Not available.

pH Not available.

Melting point/freezing point Not available.

Initial boiling point and boiling Not available.

range

Flash point Not available.

Evaporation rate Not available.

Flammability (solid, gas) Not available.

Upper/lower flammability or explosive limits

Flammability limit - lower Not

(%)

Not available.

(70)

Flammability limit - upper

Not available.

(%)

Vapour pressureNot available.Vapour densityNot available.Relative densityNot available.

Solubility(ies)

Solubility (water) Not available.

Solubility (other) Not available.

Partition coefficient Not available.

(n-octanol/water)

Auto-ignition temperature Not available.

SDS MALTA

Decomposition temperatureNot available.ViscosityNot available.Explosive propertiesNot available.Oxidizing propertiesNot available.

9.2. Other information No relevant additional information available.

SECTION 10: Stability and reactivity

10.1. Reactivity The product is stable and non-reactive under normal conditions of use, storage and transport.

10.2. Chemical stability Material is stable under normal conditions.

10.3. Possibility of hazardous

reactions

No dangerous reaction known under conditions of normal use.

10.4. Conditions to avoidContact with incompatible materials.

10.5. Incompatible materials Alkali metals. Isocyanates

10.6. Hazardous Irritating and/or toxic fumes and gases may be emitted upon the products decomposition.

decomposition products

SECTION 11: Toxicological information

General information Occupational exposure to the substance or mixture may cause adverse effects.

Information on likely routes of exposure

Inhalation Health injuries are not known or expected under normal use. Inhalation of dusts may cause

respiratory irritation.

Skin contact Health injuries are not known or expected under normal use. Dust or powder may irritate the skin.

Eye contact Health injuries are not known or expected under normal use. Direct contact with eyes may cause

temporary irritation. Dust or powder may irritate eye tissue.

Ingestion Health injuries are not known or expected under normal use. Harmful if swallowed.

Symptoms Irritant effects. Prolonged exposure may cause chronic effects.

The following adverse effects have been noted with therapeutic use of this material: bone marrow

toxicity; nausea; vomiting; diarrhoea; anorexia; rash; hair loss;.

Adverse effects might occur in the following organ(s) following overexposure: bone marrow and

formation of blood cells; liver; immune system.

11.1. Information on toxicological effects

Acute toxicity Health injuries are not known or expected under normal use. Harmful if swallowed.

Components Species Test results

MAGNESIUM STEARATE (CAS 557-04-0)

Acute

Oral

LD50 Rat > 2000 mg/kg

MERCAPTOPURINE MONOHYDRATE (CAS 6112-76-1)

Acute

Oral

LD50 Mouse 1250 mg/kg

Chronic

Oral

 LD
 Rat
 20 mg/kg/day, 6 months

 NOAEL
 Rat
 < 5 mg/kg/day, 6 months</td>

Skin corrosion/irritation Health injuries are not known or expected under normal use.

Irritation Corrosion - Skin

MERCAPTOPURINE MONOHYDRATE Acute dermal irritation; OECD 404, Primary Irritation Index: 0

Result: negative Species: Rabbit

Irritation Corrosion - Skin: P.I.I. value

MAGNESIUM STEARATE 0

Serious eye damage/eye

irritation

Health injuries are not known or expected under normal use.

Material name: PURINETHOL TABLETS

Eye

MERCAPTOPURINE MONOHYDRATE Acute ocular irritation; OECD 405, Kay and Calandra score =

4; maximum group mean score = 9,3

Result: Mild irritant Species: Rabbit IRE Assay

Result: Negative; not likely to be a severe irritant

Eye / Kay and Calandra class - Intact

MAGNESIUM STEARATE

Recovery Period: 2 days

Respiratory sensitisation Not available

Skin sensitisation Health injuries are not known or expected under normal use.

Health injuries are not known or expected under normal use. Contains a component that produced Germ cell mutagenicity

mutagenicity in laboratory tests.

Mutagenicity

MERCAPTOPURINE MONOHYDRATE Ames Assay, GLP assay

Result: positive

Chromosomal Aberration Assay In Vitro, human peripheral

lymphocytes Result: positive

Mammalian cell mutation assay (CHO/HGPRT forward

mutation assay) Result: positive

Mouse Lymphoma Cell (L5178Y) Mutation Assay, GLP assay

Result: positive

Unscheduled DNA Synthesis, in vivo - in vitro

Result: negative

Health injuries are not known or expected under normal use. Contains a component listed as a Carcinogenicity

carcinogen by: (GSK).

This material contains components which have been classified as: Possible reproductive hazard. Reproductive toxicity

May damage fertility. Potential embryo-foetal toxicity and teratogenicity. May cause harm to

breastfed babies.

Specific target organ toxicity -

single exposure

None known.

Specific target organ toxicity -

repeated exposure

May cause damage to organs through prolonged or repeated exposure.

Repeat dose non-clinical studies; clinical observation Organ: Bone marrow; liver; immune system

Not available. **Aspiration hazard**

MERCAPTOPURINE MONOHYDRATE

Mixture versus substance

information

No information available.

Other information Symptoms may be delayed.

SECTION 12: Ecological information

Contains a substance which causes risk of hazardous effects to the environment. 12.1. Toxicity

Components **Species** Test results

MAGNESIUM STEARATE (CAS 557-04-0)

Aquatic

Acute

Fish EC50 Orange-red killfish (Adult Oryzias 130 mg/l, 96 hours

latipes)

MERCAPTOPURINE MONOHYDRATE (CAS 6112-76-1)

Acute

IC50 Activated sludge > 1000 mg/l, 3 hours Aquatic

Acute

Material name: PURINETHOL TABLETS

Algae EC50 Green algae (Scenedesmus > 100 mg/l, 72 hours Static test

subspicatus)

NOEC Green algae (Scenedesmus 100 mg/l, 72 hours Static test

subspicatus)

Crustacea EC50 Water flea (Daphnia magna) 72 mg/l, 48 hours Static test

> NOEC Water flea (Daphnia magna) 32 mg/l, 48 hours Static test

110573 Version #: 17 Revision date: 20-October-2014 Issue date: 20-October-2014

12.2. Persistence and degradability

Photolysis

Half-life (Photolysis-atmospheric)

MAGNESIUM STEARATE 17 Hours Estimated

UV/visible spectrum wavelength

MAGNESIUM STEARATE 210 nm

Hydrolysis

Half-life (Hydrolysis-neutral)

MERCAPTOPURINE MONOHYDRATE 34 - 88 Days Measured, pH 7 Buffer Solution

Biodegradability

Percent degradation (Aerobic biodegradation-inherent)

MAGNESIUM STEARATE 77 %, 28 days BOD

MERCAPTOPURINE MONOHYDRATE < 1 %, 28 days Modified Zahn-Wellens, Activated sludge

Percent degradation (Aerobic biodegradation-ready)

MAGNESIUM STEARATE 95 %, 22 days Sturm test

MERCAPTOPURINE MONOHYDRATE 11 %, 28 days Modified Sturm test.

Percent degradation (Aerobic biodegradation-soil)

MAGNESIUM STEARATE 50 %, 13 days

12.3. Bioaccumulative potential

Partition coefficient n-octanol/water (log Kow)

MERCAPTOPURINE MONOHYDRATE < -2,03

Bioconcentration factor (BCF)

MAGNESIUM STEARATE > 9999 Estimated

12.4. Mobility in soil No data available.

Adsorption

Soil/sediment sorption - log Koc

MAGNESIUM STEARATE 5,86 Estimated

Mobility in generalNot available.12.5. Results of PBTNot available.

and vPvB assessment

12.6. Other adverse effects Not available.

SECTION 13: Disposal considerations

13.1. Waste treatment methods

Residual waste Dispose of in accordance with local regulations. Empty containers or liners may retain some

product residues. This material and its container must be disposed of in a safe manner (see:

Disposal instructions).

Contaminated packaging Empty containers should be taken to an approved waste handling site for recycling or disposal.

Since emptied containers may retain product residue, follow label warnings even after container is

emptied.

EU waste codeThe Waste code should be assigned in discussion between the user, the producer and the waste

disposal company.

Disposal methods/information Collect and reclaim or dispose in sealed containers at licensed waste disposal site. Do not allow

this material to drain into sewers/water supplies. Do not contaminate ponds, waterways or ditches

with chemical or used container. Dispose of contents/container in accordance with

local/regional/national/international regulations.

Special precautions Dispose in accordance with all applicable regulations.

SECTION 14: Transport information

ADR

Not regulated as dangerous goods.

IATA

Not regulated as dangerous goods.

IMDG

Not regulated as dangerous goods.

14.7. Transport in bulk Not applicable.

according to Annex II of

MARPOL73/78 and the IBC Code

Material name: PURINETHOL TABLETS

SECTION 15: Regulatory information

15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

EU regulations

Regulation (EC) No. 1005/2009 on substances that deplete the ozone layer, Annex I

Regulation (EC) No. 1005/2009 on substances that deplete the ozone layer, Annex II

Regulation (EC) No. 850/2004 On persistent organic pollutants, Annex I as amended

Not listed.

Regulation (EC) No. 689/2008 concerning the export and import of dangerous chemicals, Annex I, part 1 as amended Not listed.

Regulation (EC) No. 689/2008 concerning the export and import of dangerous chemicals, Annex I, part 2 as amended Not listed.

Regulation (EC) No. 689/2008 concerning the export and import of dangerous chemicals, Annex I, part 3 as amended

Regulation (EC) No. 689/2008 concerning the export and import of dangerous chemicals, Annex V as amended

Regulation (EC) No. 166/2006 Annex II Pollutant Release and Transfer Registry

Regulation (EC) No. 1907/2006, REACH Article 59(10) Candidate List as currently published by ECHA

Not listed.

Authorisations

Regulation (EC) No. 1907/2006, REACH Annex XIV Substances subject to authorization, as amended

Not listed.

Restrictions on use

Regulation (EC) No. 1907/2006, REACH Annex XVII Substances subject to restriction on marketing and use as amended

Directive 2004/37/EC: on the protection of workers from the risks related to exposure to carcinogens and mutagens at work

Not listed.

Directive 92/85/EEC: on the safety and health of pregnant workers and workers who have recently given birth or are breastfeeding

Not listed.

Other EU regulations

Directive 96/82/EC (Seveso II) on the control of major-accident hazards involving dangerous substances

Directive 98/24/EC on the protection of the health and safety of workers from the risks related to chemical agents at work Not listed.

Directive 94/33/EC on the protection of young people at work

Not listed.

Other regulations The product is classified and labelled in accordance with EC directives or respective national laws.

This Safety Data Sheet complies with the requirements of Regulation (EC) No 1907/2006. Pregnant women should not work with the product, if there is the least risk of exposure.

Young people under 18 years old are not allowed to work with this product according to the EU **National regulations**

Directive 94/33/EC on the protection of young people at work. Follow national regulation for work

with chemical agents.

15.2. Chemical safety

assessment

No Chemical Safety Assessment has been carried out.

SECTION 16: Other information

List of abbreviations Not available.

GSK Hazard Determination References

Information on evaluation method leading to the classification of mixture

The classification for health and environmental hazards is derived by a combination of calculation methods and test data, if available.

Full text of any statements or R-phrases and H-statements under Sections 2 to 15

R22 Harmful if swallowed.

R40 Limited evidence of a carcinogenic effect.

R48/22 Harmful: danger of serious damage to health by prolonged exposure if swallowed.

R52 Harmful to aquatic organisms.

Material name: PURINETHOL TABLETS

SDS MALTA

R52/53 Harmful to aquatic organisms, may cause long-term adverse effects in the aquatic environment.

R53 May cause long term adverse effects in the aquatic environment.

R60 May impair fertility.

R61 May cause harm to the unborn child. R64 May cause harm to breastfed babies. R68 Possible risk of irreversible effects.

H302 Harmful if swallowed.

H341 Suspected of causing genetic defects.

H351 Suspected of causing cancer.

H360FD May damage fertility. May damage the unborn child.

H362 May cause harm to breast-fed children.

H373 May cause damage to organs through prolonged or repeated exposure.

H412 Harmful to aquatic life with long lasting effects.

Product and Company Identification: Product and Company Identification

Composition / Information on Ingredients: Ingredients

Physical & Chemical Properties: Toxicological Information:

Ecological Information: Degradation

Regulatory Information: Risk Phrases - Class.

Training information

Revision information

Follow training instructions when handling this material.

Disclaimer

The information and recommendations in this safety data sheet are, to the best of our knowledge, accurate as of the date of issue. Nothing herein shall be deemed to create any warranty, express or implied. It is the responsibility of the user to determine the applicability of this information and the suitability of the material or product for any particular purpose.

Material name: PURINETHOL TABLETS